Read by QxMD icon Read

Sarcoma brennan

Neyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, Mark Bernstein, Gordana Jovic, Mark D Krailo, Jane M Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken L B Brown, Trude Butterfass-Bahloul, Gabriele Calaminus, Heike E Daldrup-Link, Mikael Eriksson, Mark C Gebhardt, Hans Gelderblom, Joachim Gerss, Robert Goldsby, Allen Goorin, Richard Gorlick, Holcombe E Grier, Juliet P Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S Hawkins, Knut Helmke, Pancras C W Hogendoorn, Michael S Isakoff, Katherine A Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C Lau, Patrick J Leavey, Stephen L Lessnick, Leo Mascarenhas, Paul A Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Papai, R Lor Randall, Peter Reichardt, Marleen Renard, Akmal Ahmed Safwat, Cindy L Schwartz, Michael C G Stevens, Sandra J Strauss, Lisa Teot, Mathias Werner, Matthew R Sydes, Jeremy S Whelan
BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation...
October 2016: Lancet Oncology
Leo Kager, Jeremy Whelan, Uta Dirksen, Bass Hassan, Jakob Anninga, Lindsey Bennister, Judith V M G Bovée, Bernadette Brennan, Javier M Broto, Laurence Brugières, Anne-Marie Cleton-Jansen, Christopher Copland, Aurélie Dutour, Franca Fagioli, Stefano Ferrari, Marta Fiocco, Emmy Fleuren, Nathalie Gaspar, Hans Gelderblom, Craig Gerrand, Joachim Gerß, Ornella Gonzato, Winette van der Graaf, Stefanie Hecker-Nolting, David Herrero-Martín, Stephanie Klco-Brosius, Heinrich Kovar, Ruth Ladenstein, Carlo Lancia, Marie-Cecile LeDeley, Martin G McCabe, Markus Metzler, Ola Myklebost, Michaela Nathrath, Piero Picci, Jenny Potratz, Françoise Redini, Günther H S Richter, Denise Reinke, Piotr Rutkowski, Katia Scotlandi, Sandra Strauss, David Thomas, Oscar M Tirado, Franck Tirode, Gilles Vassal, Stefan S Bielack
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations...
2016: Clinical Sarcoma Research
Stéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, Uta Dirksen, Lee Jeys, Anna Cassoni, Line Claude, Beatrice Seddon, Perrine Marec-Berard, Jeremy Whelan, Michael Paulussen, Arne Streitbuerger, Odile Oberlin, Heribert Juergens, Robert Grimer, Marie-Cécile Le Deley
BACKGROUND: The role of postoperative radiotherapy (PORT) in Ewing sarcoma (ES) is unclear. We assessed the impact of PORT on local control in patients with localised ES and good histological response to chemotherapy (<10% cells). PATIENTS AND METHODS: All randomised patients in the EE99-R1 trial (comparing two consolidation chemotherapy regimens) undergoing surgery after induction chemotherapy were included. Local relapse (LR) cumulative incidence was estimated using a competing risk approach...
July 2016: European Journal of Cancer
Craig Gerrand, Nick Athanasou, Bernadette Brennan, Robert Grimer, Ian Judson, Bruce Morland, David Peake, Beatrice Seddon, Jeremy Whelan
This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need further updates as care evolves...
2016: Clinical Sarcoma Research
Bernadette Brennan, Gian Luca De Salvo, Daniel Orbach, Angela De Paoli, Anna Kelsey, Peter Mudry, Nadine Francotte, Max Van Noesel, Gianni Bisogno, Michela Casanova, Andrea Ferrari
BACKGROUND: Extracranial malignant rhabdoid tumours (MRT) are rare lethal childhood cancers that often occur in infants and have a characteristic genetic mutation in the SMARCB1 gene. The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) conducted a multinational prospective study of registered cases of extracranial MRT to test an intensive multimodal approach of treatment for children with newly diagnosed extracranial MRT. METHODS: Between December 2005 and June 2014, we prospectively registered 100 patients from 12 countries with a diagnosis of MRT tumour at an extracranial site on the EpSSG Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study (NRSTS 2005)...
June 2016: European Journal of Cancer
Pierre Avril, Louis-Romée Le Nail, Meadhbh Á Brennan, Philippe Rosset, Gonzague De Pinieux, Pierre Layrolle, Dominique Heymann, Pierre Perrot, Valérie Trichet
Conventional therapy of primary bone tumors includes surgical excision with wide resection, which leads to physical and aesthetic defects. For reconstruction of bone and joints, allografts can be supplemented with mesenchymal stem cells (MSCs). Similarly, adipose tissue transfer (ATT) is supplemented with adipose-derived stem cells (ADSCs) to improve the efficient grafting in the correction of soft tissue defects. MSC-like cells may also be used in tumor-targeted cell therapy. However, MSC may have adverse effects on sarcoma development...
March 2016: Journal of Bone Oncology
Daniel Orbach, Bernadette Brennan, Angela De Paoli, Soledad Gallego, Peter Mudry, Nadine Francotte, Max van Noesel, Anna Kelsey, Rita Alaggio, Dominique Ranchère, Gian Luca De Salvo, Michela Casanova, Christophe Bergeron, Johannes H M Merks, Meriel Jenney, Michael C G Stevens, Gianni Bisogno, Andrea Ferrari
BACKGROUND: Infantile fibrosarcoma (IFS) is a very rare disease occurring in young infants characterised by a high local aggressiveness but overall with a favourable survival. To try to reduce the total burden of therapy, the European pediatric Soft tissue sarcoma Study Group has developed conservative therapeutic recommendations according to initial resectability. MATERIAL AND METHODS: Between 2005 and 2012, children with localised IFS were prospectively registered...
April 2016: European Journal of Cancer
Ann Y Lee, Narasimhan P Agaram, Li-Xuan Qin, Deborah Kuk, Christina Curtin, Murray F Brennan, Samuel Singer
BACKGROUND: Myxofibrosarcoma and undifferentiated pleomorphic sarcoma (UPS) are aggressive, genetically complex sarcomas. The minimum myxoid component used as a criterion for myxofibrosarcoma varies widely, so we determined the optimal myxoid component cutpoints for stratifying outcomes of UPS and myxofibrosarcoma. We also analyzed clinicopathologic factors associated with outcome. METHODS: Review of a prospective, single-institution database identified 197 patients with primary, high-grade extremity/truncal myxofibrosarcoma or UPS resected during 1992-2013...
March 2016: Annals of Surgical Oncology
Jason A Davis, Brennan Roper, John W Munz, Timothy S Achor, Matthew Galpin, Andrew M Choo, Joshua L Gary
BACKGROUND: Controversy regarding heterotopic ossification (HO) prophylaxis exists after Kocher-Langenbeck for treatment of acetabular fracture. Prophylaxis options include antiinflammatory oral medications, single-dose radiation therapy, and débridement of gluteus minimus muscle. Prior literature has suggested single-dose radiation therapy as the best prophylaxis to prevent HO formation. However, recent reports have emerged of radiation-induced sarcoma after radiotherapy for HO prophylaxis, which has led many surgeons to reconsider the risks and benefits of single-dose radiation therapy...
June 2016: Clinical Orthopaedics and related Research
Nathalie Gaspar, Douglas S Hawkins, Uta Dirksen, Ian J Lewis, Stefano Ferrari, Marie-Cecile Le Deley, Heinrich Kovar, Robert Grimer, Jeremy Whelan, Line Claude, Olivier Delattre, Michael Paulussen, Piero Picci, Kirsten Sundby Hall, Hendrik van den Berg, Ruth Ladenstein, Jean Michon, Lars Hjorth, Ian Judson, Roberto Luksch, Mark L Bernstein, Perrine Marec-Bérard, Bernadette Brennan, Alan W Craft, Richard B Womer, Heribert Juergens, Odile Oberlin
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists...
September 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Aimee M Crago, Murray F Brennan
No abstract text is available yet for this article.
2015: Advances in Surgery
Henk van den Berg, Michael Paulussen, Gwénaël Le Teuff, Ian Judson, Hans Gelderblom, Uta Dirksen, Bernadette Brennan, Jeremy Whelan, Ruth Lydia Ladenstein, Perrine Marec-Berard, Jarmila Kruseova, Lars Hjorth, Thomas Kühne, Benedicte Brichard, Keith Wheatley, Alan Craft, Heribert Juergens, Nathalie Gaspar, Marie-Cécile Le Deley
BACKGROUND: Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity. PATIENTS AND METHODS: Impact of gender on event-free survival (EFS), acute toxicity by course, switches between treatment arms and cumulative dose of alkylating agents was evaluated in multivariable models adjusted for age including terms to test for heterogeneity of treatment effect by gender...
November 2015: European Journal of Cancer
Kaitlyn J Kelly, Sam S Yoon, Deborah Kuk, Li-Xuan Qin, Katerina Dukleska, Kevin K Chang, Yen-Lin Chen, Thomas F Delaney, Murray F Brennan, Samuel Singer
OBJECTIVE: To compare outcomes of patients with retroperitoneal or pelvic sarcoma treated with perioperative radiation therapy (RT) versus those treated without perioperative RT. BACKGROUND: RT for retroperitoneal or pelvic sarcoma is controversial, and few studies have compared outcomes with and without RT. METHODS: Prospectively maintained databases were reviewed to retrospectively compare patients with primary retroperitoneal or pelvic sarcoma treated during 2003-2011...
July 2015: Annals of Surgery
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R Chalmers, Savina Jaeger, Alan Huang, Julia A Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle A Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S Ross, Eric Collisson, Malte Peters, Philip J Stephens, Vincent A Miller
UNLABELLED: Focal amplification and activating point mutation of the MET gene are well-characterized oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic splice site alterations at MET exon 14 (METex14) that result in exon skipping and MET activation have been characterized, but their full diversity and prevalence across tumor types are unknown. Here, we report analysis of tumor genomic profiles from 38,028 patients to identify 221 cases with METex14 mutations (0...
August 2015: Cancer Discovery
Marcus C B Tan, Murray F Brennan, Deborah Kuk, Narasimhan P Agaram, Cristina R Antonescu, Li-Xuan Qin, Nicole Moraco, Aimee M Crago, Samuel Singer
OBJECTIVE: To determine the prognostic significance of histologic type/subtype in a large series of patients with primary resected retroperitoneal sarcoma. BACKGROUND: The histologic diversity and rarity of retroperitoneal sarcoma has hampered the ability to predict patient outcome. METHODS: From a single-institution, prospective database, 675 patients treated surgically for primary, nonmetastatic retroperitoneal sarcoma during 1982 to 2010 were identified and histologic type/subtype was reviewed...
March 2016: Annals of Surgery
Andrew G Shuman, Murray F Brennan, Frank L Palmer, Deborah Kuk, Nicole Moraco, Samuel Singer, Jatin P Shah, Snehal G Patel
BACKGROUND AND OBJECTIVES: Soft tissue sarcomas of the head and neck (STSHN) comprise a rare group of malignancies. Our objective is to determine the utility of soft tissue sarcoma staging systems within the head and neck, and to validate an individualized soft tissue sarcoma nomogram within head and neck primary sites. METHODS: Previously-untreated patients with STSHN diagnosed and treated between 1982 and 2012 were eligible (n = 319, median follow-up 46 months)...
May 2015: Journal of Surgical Oncology
A Ferrari, G L De Salvo, B Brennan, M M van Noesel, A De Paoli, M Casanova, N Francotte, A Kelsey, R Alaggio, O Oberlin, M Carli, M Ben-Arush, C Bergeron, J H M Merks, M Jenney, M C Stevens, G Bisogno, D Orbach
BACKGROUND: To report the results of the first European prospective nonrandomized trial dedicated to pediatric synovial sarcoma. PATIENTS AND METHODS: From August 2005 to August 2012, 138 patients <21 years old with nonmetastatic synovial sarcoma were registered in 9 different countries (and 60 centers). Patients were treated with a multimodal therapy including ifosfamide-doxorubicin chemotherapy and radiotherapy, according to a risk stratification based on surgical stage, tumor size and site, and nodal involvement...
March 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
R C Brennan, W Furman, S Mao, J Wu, D C Turner, C F Stewart, V Santana, L M McGregor
PURPOSE: This phase I study endeavored to estimate the maximum tolerated dose and describe the dose-limiting toxicities (DLTs) of oral irinotecan with gefitinib in children with refractory solid tumors. METHODS: Oral irinotecan was administered on days 1-5 and 8-12 with oral gefitinib (fixed dose, 150 mg/m(2)/day) on days 1-12 of a 21-day course. The escalation with overdose control method guided irinotecan dose escalation (7 dose levels, range 5-40 mg/m(2)/day)...
December 2014: Cancer Chemotherapy and Pharmacology
Michael R Folkert, Samuel Singer, Murray F Brennan, Deborah Kuk, Li-Xuan Qin, Wendy K Kobayashi, Aimee M Crago, Kaled M Alektiar
PURPOSE: The use of intensity-modulated radiation therapy (IMRT) in the treatment of soft tissue sarcoma (STS) of the extremity is increasing, but no large-scale direct comparison has been reported between conventional external-beam radiation therapy (EBRT) and IMRT. METHODS: Between January 1996 and December 2010, 319 consecutive adult patients with primary nonmetastatic extremity STS were treated with limb-sparing surgery and adjuvant radiotherapy (RT) at a single institution...
October 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Murray F Brennan, Cristina R Antonescu, Nicole Moraco, Samuel Singer
BACKGROUND AND OBJECTIVE: The management of rare tumors is difficult because of limited information on natural history. Our objective was to describe a long-term comprehensive prospective database with the assumption that with careful attention to patient, predisposing tumor and treatment variables, valuable knowledge could be obtained that could guide management. METHODS: In July of 1982, we began a prospective database of all adult patients admitted to our institution for a surgical procedure for soft tissue sarcoma...
September 2014: Annals of Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"